All terms in EFO
| Label | Id | Description |
|---|---|---|
| biliverdin measurement | EFO_0021033 | [Quantification of the amount of biliverdin in a sample.] |
| cryptic phenotype measurement | EFO_0021487 | [Quantification of disease-related phenotypic variability using qualitative symptom data.] |
| obsolete_familial recurrent peripheral facial palsy | Orphanet_2809 | |
| Heterogeneous | HP_0001425 | |
| treprostinil dose measurement | EFO_0021489 | [Quantification of some aspect of treprostinil dosage.] |
| triacylglycerol 53:2 measurement | EFO_0021484 | [Quantification of triacylglycerol 53:2 in a sample.] |
| triacylglycerol 51:2 measurement | EFO_0021483 | [Quantification of triacylglycerol 51:2 in a sample.] |
| Partial pancreatic agenesis | Orphanet_2805 | |
| ubiquinone measurement | EFO_0021486 | [Quantification of ubiquinone in a sample.] |
| W syndrome | Orphanet_2804 | |
| triacylglycerol 54:0 measurement | EFO_0021485 | [Quantification of triacylglycerol 54:0 in a sample.] |
| triacylglycerol 50:0 measurement | EFO_0021480 | [Quantification of triacylglycerol 50:0 in a sample.] |
| 1q21.1 microdeletion syndrome | Orphanet_250989 | [1q21.1 microdeletion syndrome is a newly described recurrent deletion syndrome with variable clinical manifestations but without the clinical picture of thrombocytopenia - absent radius (TAR) syndrome.] |
| Partial deletion of the long arm of chromosome 1 | Orphanet_262001 | |
| triacylglycerol 51:1 measurement | EFO_0021482 | [Quantification of triacylglycerol 51:1 in a sample.] |
| triacylglycerol 51:0 measurement | EFO_0021481 | [Quantification of triacylglycerol 51:0 in a sample.] |
| Biomphalaria glabrata | NCBITaxon_6526 | |
| Darier disease | MONDO_0007417 | [Darier disease (DD) is a keratinization disorder characterized by the development of keratotic papules in seborrheic areas and specific nail anomalies.] |
| Gorham-Stout disease | MONDO_0007414 | [Gorham-Stout disease (GSD) is a rare disease of massive osteolysis associated with proliferation and dilation of lymphatic vessels. GSD may affect any bone in the body and can be monostotic or polyostotic. Symptoms at presentation are dependent upon the location(s) of the disease; the most common symptom is localized pain. The disease may be discovered after a pathological fracture.] |
| disappearing bone disease | MONDO_0003157 | [Syndromes of bone destruction where the cause is not obvious such as neoplasia, infection, or trauma. The destruction follows various patterns: massive (Gorham disease), multicentric (hajdu-cheney syndrome), or carpal/tarsal.] |